Nyra Medical's Carlen TMVr System Wins Prestigious 2026 Jon DeHaan Cardiovascular Innovation Award

Jun 20, 2026 07:00 CST Updated 07:00

Nyra Medical

Medical Device Developer

In the field of interventional cardiology, every technological innovation serves as a safety net for life.

At the 2026 EuroPCR Congress in Paris, a prestigious award of significant interest to the global cardiovascular community was officially announced!

Nyra Medical Wins the 2026 Jon DeHaan Foundation Cardiovascular Innovation Award for Its Proprietary Carlen Transcatheter Mitral Valve Repair (TMVr) System!

Those familiar with the industry know that this award carries immense prestige, serving as a “barometer” for innovation in cardiovascular medical care. It is bestowed exclusively upon top-tier technologies that address core clinical challenges, offer breakthrough value, and truly benefit a vast number of patients, making it one of the most authoritative honors in the global field of cardiac intervention.

The Carlen System’s award represents not only the industry’s highest recognition of this technology, but also signifies that millions of patients with mitral regurgitation finally have access to a new repair treatment option that is safer, better suited, and more patient-centered.

Top-Tier Authoritative Certification! Major Honor in the Field of Mitral Valve Innovation

Many people are unaware that the Jon DeHaan Foundation Cardiovascular Innovation Award is a prestigious honor in the global field of cardiovascular intervention, carrying significant weight.

Unlike conventional industry awards, this award focuses on cutting-edge breakthroughs in the global cardiovascular field. Its selection criteria are extremely rigorous, comprehensively evaluating candidates across six dimensions: urgent clinical needs, technological originality, patent barriers, clinical validation outcomes, regulatory compliance for implementation, and potential for commercial adoption.

The core mission of the award is clear: to specifically select disruptive medical technologies that address key clinical challenges in cardiovascular care, possess substantial innovative value, and significantly improve patient outcomes.

Past award-winning technologies have all been benchmark achievements that lead industry development and reshape diagnostic and treatment standards, demonstrating that the Carlen system’s recent award is well-deserved and a comprehensive testament to its strength.

Foundation Trustee Tom DeHaan remarked at the award ceremony: “Nyra Medical’s CARLEN technology breaks away from the conventional paradigm of mitral valve repair, offering a mature and uniquely innovative approach that brings a differentiated, highly forward-looking new solution to the field.”

Millions Face Dilemma! Long-standing Gaps in Mitral Regurgitation Treatment

Functional mitral regurgitation (FMR) is one of the most common valvular heart diseases in clinical practice, affecting over 10 million people worldwide, and remains a challenging issue that has troubled cardiovascular physicians for many years.

Simply put, mitral valve regurgitation occurs when the mitral valve fails to close properly, causing blood to flow backward. This condition is highly insidious in its early stages yet poses severe risks; if left untreated over time, it can progressively lead to cardiac enlargement and heart failure, significantly increasing patient disability and mortality rates. It not only affects tens of millions of patients worldwide but also imposes a substantial burden on healthcare systems globally.

However, for a long time, clinical treatment has been trapped in a dilemma:

Traditional open-chest surgical mitral valve repair is highly invasive and carries significant surgical risk, making it largely intolerable for high-risk patients who are elderly or have multiple comorbidities. In contrast, while currently mainstream transcatheter minimally invasive repair techniques avoid the trauma of open-chest surgery, they suffer from core limitations, including a narrow patient population, damage to the native mitral valve structure, and restriction of future treatment options for patients.

A significant number of patients with severe mitral regurgitation face the dilemma of having no suitable minimally invasive treatment options, representing a critical unmet clinical need urgently requiring resolution in the global field of transcatheter valve interventions.

The Nyra Medical Carlen Mitral Valve Repair System was developed to precisely address this clinical gap, offering a novel solution for patients with complex mitral regurgitation!

Industry-Disruptive Breakthrough! Novel Protective Mitral Valve Repair Technology

Compared with traditional valve intervention techniques, the most significant innovation of the Carlen transcatheter mitral valve repair (TMVr) system is its complete departure from the conventional "destructive repair" model, pioneering a new paradigm for protective repair that preserves the native mitral valve structure.

Traditional minimally invasive mitral valve repair techniques cause irreversible damage to the patient’s native mitral valve, constituting a one-time repair approach. Should the patient’s condition change postoperatively, there is virtually no room for secondary repair or optimized treatment, resulting in inadequate prognostic assurance.

Nyra Medical initiates first-in-human study of heart implant

The Carlen system adopts a completely new design philosophy, with exceptionally prominent core advantages:

Preservation of Native Valve Function: The normal structure of the patient’s own cardiac valves is preserved, maximizing protection of the heart’s native physiological function;

Precise Lesion Repair: By optimizing leaflet coaptation, this approach efficiently resolves blood regurgitation, ensuring precise and controllable therapeutic outcomes;

Reserve space for subsequent treatment: Maintain flexibility for future cardiac diagnosis and treatment, providing a safety net for the patient’s potential therapeutic needs.

Broader Patient Population: Covers a large number of patients with functional mitral regurgitation who are ineligible for or difficult to treat with conventional technologies.

Lori Chmura, CEO of Nyra Medical, stated that the core intention behind developing the Carlen system was to overcome the many limitations of existing mitral valve repair technologies. By adopting a simpler, more flexible, and safer minimally invasive approach, the system aims to break through traditional treatment barriers, providing effective, durable, and well-supported care to more patients with mitral regurgitation who are currently excluded by conventional techniques.

Impressive Clinical Data! Earns Global Authoritative Recognition in the Valve Field

Currently, the Carlen system has successfully completed its first-in-human clinical trial, with impressive interim clinical results that fully validate the feasibility and safety of the technology.

At the EuroPCR 2026 conference in Paris, Susheel Kodali, a leading expert from NewYork-Presbyterian/Columbia University Irving Medical Center in the United States, publicly shared the early clinical outcomes of this technology.

Promising Early Clinical Data: The Carlen System Demonstrates Excellent Safety, Precisely Corrects Mitral Regurgitation, and Effectively Restores Normal Cardiac Function, with Overall Efficacy Far Exceeding Expectations for Traditional Minimally Invasive Repair Approaches.

Professor Kodali spoke highly of this technology: “In clinical practice, we have long desired a new technology that can efficiently correct mitral regurgitation while preserving the patient’s native cardiac anatomy and not precluding future treatment options. The early clinical results of the Carlen system have opened up a new direction in the field of minimally invasive mitral valve repair, demonstrating significant value for both clinical research and widespread adoption.”

Technology Empowers Valve Diagnosis and Treatment! Bringing New Hope to Millions of Patients

Addressing clinical pain points, empowering healthcare with technological innovation, and winning top international awards with robust capabilities.

The Carlen System’s award is not only a milestone for Nyra Medical, but also a major breakthrough in the global field of mitral regurgitation diagnosis and treatment.

In the past, a vast number of patients with mitral regurgitation faced a dilemma: either endure the significant trauma and risks associated with open-chest surgery, or accept traditional minimally invasive approaches that had limitations and restricted subsequent treatment options, leaving many patients without the most suitable therapy.

The advent of the Carlen mitral valve repair technique has redefined the standards for minimally invasive high-end valvular repair: it preserves native mitral valve structures, offers a minimally invasive and safe approach with stable efficacy, and reserves future treatment options, thereby truly achieving the therapeutic goals of precision cure and long-term protection.

In the future, as clinical research on this mitral valve repair technology continues to advance and its application becomes increasingly widespread, tens of millions of patients with functional mitral regurgitation will be completely freed from the plight of having no access to treatment or facing treatment limitations, ushering in a new era of higher-quality, safer minimally invasive diagnostic and therapeutic options.

The essence of medical innovation lies in leveraging technology to bridge gaps in diagnosis and treatment, thereby safeguarding public health. This breakthrough in cutting-edge mitral valve technology represents not only a significant advancement in the field of interventional valvular therapy but also a beacon of hope for millions of cardiac patients. We look forward to further iterative innovations in valvular medical technologies, bringing greater benefits to more patients!

End-of-Article Interaction

Are you optimistic about this groundbreaking new minimally invasive mitral valve repair technology? Share your thoughts in the comments! Follow me to stay updated on top-tier global innovations in heart valve medicine and gain early access to cutting-edge diagnostic and therapeutic techniques.